• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项全州范围内自愿进行的脊髓性肌萎缩症新生儿筛查试点:早期检查结果。

A Voluntary Statewide Newborn Screening Pilot for Spinal Muscular Atrophy: Results from Early Check.

作者信息

Kucera Katerina S, Taylor Jennifer L, Robles Veronica R, Clinard Kristin, Migliore Brooke, Boyea Beth Lincoln, Okoniewski Katherine C, Duparc Martin, Rehder Catherine W, Shone Scott M, Fan Zheng, Raspa Melissa, Peay Holly L, Wheeler Anne C, Powell Cynthia M, Bailey Donald B, Gehtland Lisa M

机构信息

RTI International, Research Triangle Park, Durham, NC 27709, USA.

American College of Medical Genetics and Genomics, Bethesda, MD 20814, USA.

出版信息

Int J Neonatal Screen. 2021 Mar 21;7(1):20. doi: 10.3390/ijns7010020.

DOI:10.3390/ijns7010020
PMID:33801060
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8006221/
Abstract

Prior to statewide newborn screening (NBS) for spinal muscular atrophy (SMA) in North Carolina, U.S.A., we offered voluntary screening through the Early Check (EC) research study. Here, we describe the EC experience from October 2018 through December 2020. We enrolled a total of 12,065 newborns and identified one newborn with 0 copies of and two copies of , consistent with severe early onset of SMA. We also detected one false positive result, likely stemming from an unrelated blood disorder associated with a low white blood cell count. We evaluated the timing of NBS for babies enrolled prenatally ( = 932) and postnatally ( = 11,133) and reasons for delays in screening and reporting. Although prenatal enrollment led to faster return of results (median = 13 days after birth), results for babies enrolled postnatally were still available within a timeframe (median = 21 days after birth) that allowed the opportunity to receive essential treatment early in life. We evaluated an SMA q-PCR screening method at two separate time points, confirming the robustness of the assay. The pilot project provided important information about SMA screening in anticipation of forthcoming statewide expansion as part of regular NBS.

摘要

在美国北卡罗来纳州开展全州范围的脊髓性肌萎缩症(SMA)新生儿筛查(NBS)之前,我们通过早期检查(EC)研究开展了自愿筛查。在此,我们描述2018年10月至2020年12月期间的EC筛查情况。我们共招募了12,065名新生儿,发现1名新生儿为SMN1基因0拷贝且SMN2基因2拷贝,符合SMA严重早发型。我们还检测到1例假阳性结果,可能源于与白细胞计数低相关的一种无关血液疾病。我们评估了产前(n = 932)和产后(n = 11,133)登记入组婴儿的NBS时间以及筛查和报告延迟的原因。尽管产前登记入组导致结果返回更快(出生后中位数 = 13天),但产后登记入组婴儿的结果仍能在一个时间范围内获得(出生后中位数 = 21天),这使得有机会在生命早期接受必要治疗。我们在两个不同时间点评估了一种SMA定量聚合酶链反应(q-PCR)筛查方法,证实了该检测方法的稳健性。该试点项目为即将作为常规NBS一部分在全州范围内扩大SMA筛查提供了重要信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/137f87d8b94c/IJNS-07-00020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/7f79e7816d32/IJNS-07-00020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/ecc0a4cfb162/IJNS-07-00020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/137f87d8b94c/IJNS-07-00020-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/7f79e7816d32/IJNS-07-00020-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/ecc0a4cfb162/IJNS-07-00020-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e12/8006221/137f87d8b94c/IJNS-07-00020-g003.jpg

相似文献

1
A Voluntary Statewide Newborn Screening Pilot for Spinal Muscular Atrophy: Results from Early Check.一项全州范围内自愿进行的脊髓性肌萎缩症新生儿筛查试点:早期检查结果。
Int J Neonatal Screen. 2021 Mar 21;7(1):20. doi: 10.3390/ijns7010020.
2
Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?通过新生儿筛查诊断出患有脊髓性肌萎缩症和 4 个 SMN2 拷贝的婴儿 - 是机会还是负担?
J Neuromuscul Dis. 2020;7(2):109-117. doi: 10.3233/JND-200475.
3
Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening.通过新生儿筛查对脊髓性肌萎缩症进行症状前诊断。
J Pediatr. 2017 Nov;190:124-129.e1. doi: 10.1016/j.jpeds.2017.06.042. Epub 2017 Jul 12.
4
Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations.新生儿脊髓性肌萎缩症筛查:安大略省检测和随访建议。
Can J Neurol Sci. 2021 Jul;48(4):504-511. doi: 10.1017/cjn.2020.229. Epub 2020 Oct 16.
5
Massachusetts' Findings from Statewide Newborn Screening for Spinal Muscular Atrophy.马萨诸塞州全州新生儿脊髓性肌萎缩症筛查结果
Int J Neonatal Screen. 2021 May 23;7(2):26. doi: 10.3390/ijns7020026.
6
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years.德国脊髓性肌萎缩症新生儿筛查:2 年后的临床结果。
Orphanet J Rare Dis. 2021 Mar 31;16(1):153. doi: 10.1186/s13023-021-01783-8.
7
Newborn screening for spinal muscular atrophy: The Wisconsin first year experience.脊髓性肌萎缩症的新生儿筛查:威斯康星州第一年的经验。
Neuromuscul Disord. 2022 Feb;32(2):135-141. doi: 10.1016/j.nmd.2021.07.398. Epub 2021 Jul 27.
8
Newborn Screening for Spinal Muscular Atrophy in China Using DNA Mass Spectrometry.中国使用DNA质谱法进行脊髓性肌萎缩症的新生儿筛查。
Front Genet. 2019 Dec 17;10:1255. doi: 10.3389/fgene.2019.01255. eCollection 2019.
9
One-Year Pilot Study Results of Newborn Screening for Spinal Muscular Atrophy in the Republic of Croatia.克罗地亚共和国脊髓性肌萎缩症新生儿筛查的一年试点研究结果
Int J Neonatal Screen. 2024 Jul 16;10(3):50. doi: 10.3390/ijns10030050.
10
Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme.将脊髓性肌萎缩症新生儿筛查纳入医疗保健系统:澳大利亚试点项目。
Dev Med Child Neurol. 2022 May;64(5):625-632. doi: 10.1111/dmcn.15117. Epub 2021 Nov 28.

引用本文的文献

1
Feasibility and clinical utility of expanded genomic newborn screening in the Early Check program.早期筛查项目中扩展基因组新生儿筛查的可行性及临床应用价值
Nat Med. 2025 Sep 5. doi: 10.1038/s41591-025-03945-8.
2
Performance of cellulose-based card for direct genetic testing of spinal muscular atrophy.基于纤维素的卡片用于脊髓性肌萎缩症直接基因检测的性能
BMC Biotechnol. 2025 Feb 14;25(1):17. doi: 10.1186/s12896-024-00938-2.
3
Why should a 5q spinal muscular atrophy neonatal screening program be started?为什么要启动 5q 脊髓性肌萎缩症新生儿筛查项目?

本文引用的文献

1
Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy.脊髓性肌萎缩症新生儿筛查及症状前诊断的进展
Degener Neurol Neuromuscul Dis. 2020 Dec 15;10:39-47. doi: 10.2147/DNND.S246907. eCollection 2020.
2
Intragenic and structural variation in the locus and clinical variability in spinal muscular atrophy.该位点的基因内和结构变异与脊髓性肌萎缩症的临床变异性
Brain Commun. 2020 Jun 8;2(2):fcaa075. doi: 10.1093/braincomms/fcaa075. eCollection 2020.
3
Implementation of population-based newborn screening reveals low incidence of spinal muscular atrophy.
Arq Neuropsiquiatr. 2024 Oct;82(10):1-9. doi: 10.1055/s-0044-1791201. Epub 2024 Oct 13.
4
A systematic framework for selecting gene-condition pairs for inclusion in newborn sequencing panels: Early Check implementation.用于选择纳入新生儿测序面板的基因-疾病对的系统框架:早期检查实施
Genet Med. 2024 Dec;26(12):101290. doi: 10.1016/j.gim.2024.101290. Epub 2024 Oct 5.
5
Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy.脊髓性肌萎缩症症状前治疗的系统评价
Int J Neonatal Screen. 2024 Aug 14;10(3):56. doi: 10.3390/ijns10030056.
6
Systematic Review of Newborn Screening Programmes for Spinal Muscular Atrophy.脊髓性肌萎缩症新生儿筛查项目的系统评价
Int J Neonatal Screen. 2024 Jul 15;10(3):49. doi: 10.3390/ijns10030049.
7
Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).《2024年全球新生儿血斑筛查现状:2020 - 2023年近期活动综合回顾》
Int J Neonatal Screen. 2024 May 23;10(2):38. doi: 10.3390/ijns10020038.
8
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians.脊髓性肌萎缩症的治疗选择:临床医生的实用方法。
Drugs. 2024 Jul;84(7):747-762. doi: 10.1007/s40265-024-02051-2. Epub 2024 Jun 15.
9
The Importance of Early Treatment of Inherited Neuromuscular Conditions.遗传性神经肌肉疾病的早期治疗的重要性。
J Neuromuscul Dis. 2024;11(2):253-274. doi: 10.3233/JND-230189.
10
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review.脊髓性肌萎缩症治疗在新生儿筛查识别患者中的应用:系统评价。
Genes (Basel). 2023 Jun 29;14(7):1377. doi: 10.3390/genes14071377.
基于人群的新生儿筛查的实施揭示了脊髓性肌萎缩症的低发病率。
Genet Med. 2020 Aug;22(8):1296-1302. doi: 10.1038/s41436-020-0824-3. Epub 2020 May 18.
4
Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives.支持脊髓性肌萎缩症患者早期治疗的临床证据:当前观点
Ther Clin Risk Manag. 2019 Oct 2;15:1153-1161. doi: 10.2147/TCRM.S172291. eCollection 2019.
5
The implementation of newborn screening for spinal muscular atrophy: the Australian experience.脊髓性肌萎缩症新生儿筛查的实施:澳大利亚的经验。
Genet Med. 2020 Mar;22(3):557-565. doi: 10.1038/s41436-019-0673-0. Epub 2019 Oct 14.
6
One Year of Newborn Screening for SMA - Results of a German Pilot Project.脊髓性肌萎缩症新生儿筛查的一年:德国试点项目的结果。
J Neuromuscul Dis. 2019;6(4):503-515. doi: 10.3233/JND-190428.
7
High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR.高通量基因新生儿脊髓性肌萎缩症筛查:快速从干血斑提取核酸和 384 孔 qPCR。
Eur J Hum Genet. 2020 Jan;28(1):23-30. doi: 10.1038/s41431-019-0476-4. Epub 2019 Jul 30.
8
Early Check: translational science at the intersection of public health and newborn screening.早期检查:公共卫生与新生儿筛查交叉领域的转化科学
BMC Pediatr. 2019 Jul 17;19(1):238. doi: 10.1186/s12887-019-1606-4.
9
Newborn screening for SMA in Southern Belgium.在比利时南部进行 SMA 的新生儿筛查。
Neuromuscul Disord. 2019 May;29(5):343-349. doi: 10.1016/j.nmd.2019.02.003. Epub 2019 Feb 15.
10
Pilot study of population-based newborn screening for spinal muscular atrophy in New York state.纽约州基于人群的脊髓性肌萎缩症新生儿筛查的初步研究。
Genet Med. 2018 Jun;20(6):608-613. doi: 10.1038/gim.2017.152. Epub 2017 Oct 12.